• Research and Demonstration Projects: Botswana was the site of the TDF2 trial, one of the early efficacy studies substantiating proof of concept of TDF/FTC for prevention in heterosexual men and women. There was a subsequent open-label extension trial—results of which were released in 2015.
  • Drug Registration: Truvada is registered for treatment. It is not registered for prevention.
  • Policy/Regulatory: Botswana incorporated PrEP into its 2016 HIV Clinical Care Guidelines. TDF/FTC for PrEP is technically, currently available in the private sector but will be publically available and funded in 2017.
  • Advocacy: There is demand among the gay population but there is a great need for mobilization and communication campaigns among others. Thus far BOFWA, BONELA and ITPC, along with Botswana Ministry of Health and UNAIDS Botswana are participating in early stages of shaping eventual rollout.

Last updated on September 1, 2017.

News Spotlight